Inclusion Criteria : 
   1.  Male or female subject  18 years of age or older
   2.  Subjects with moderate to severe DLE with at least one active discoid target lesion (  0.5 -  1.0 cm 2 )  , with CLASI â‰¥  5. 
   3.  Willingness of subject to follow all study procedures
   4.  Willingness to avoid excessive exposure of diseased areas to natural or artificial sunlight
Exclusion Criteria : 
   1.  Pregnancy or breast feeding
   2.  Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study
   3.  Systemic Lupus Erythematosus ( SLE ) as defined by ACR criteria
   4.  Known hypersensitivity to any of the constituents or excipients of the investigational product
   5.  Use of any prescription or non - prescription medication that could interfere with efficacy evaluations in the study
   6.  Change in use of systemic DLE therapy , e . g .  systemic corticosteroids , cyclosporine A , azathioprine , mycophenolate mofetil , in the past  1 month . 
   7.  Use of systemic pain medications , e . g .  oxycodone in the past  2 weeks
   8.  Participation in another clinical research study with an investigational drug within  4 weeks before this study
   9.  Use of immune - suppressant or other biological treatment
  10.  Starting antimalarial medicine after enrolling in the study .  Subjects who are already on a stable dose of antimalarial before enrollment , may continue the same dose . 
  11.  An ongoing infection .